These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35293331)

  • 41. Debates in gout management.
    Abhishek A
    Curr Opin Rheumatol; 2020 Mar; 32(2):134-139. PubMed ID: 31842034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
    Uhlig T; Eskild T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Dalbeth N; Hammer HB
    Rheumatology (Oxford); 2022 Apr; 61(SI):SI81-SI85. PubMed ID: 34247224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of acute and chronic gouty arthritis: present state-of-the-art.
    Schlesinger N
    Drugs; 2004; 64(21):2399-416. PubMed ID: 15481999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The management of gout at an academic healthcare center in Beijing: a physician survey.
    Fang W; Zeng X; Li M; Chen LX; Schumacher HR; Zhang F
    J Rheumatol; 2006 Oct; 33(10):2041-9. PubMed ID: 17014019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis.
    Son CN; Stewart S; Su I; Mihov B; Gamble G; Dalbeth N
    Semin Arthritis Rheum; 2021 Aug; 51(4):677-684. PubMed ID: 34139520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management and Cure of Gouty Arthritis.
    Keller SF; Mandell BF
    Rheum Dis Clin North Am; 2022 May; 48(2):479-492. PubMed ID: 35400373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.
    Stuart RA; Gow PJ; Bellamy N; Campbell J; Grigor R
    N Z Med J; 1991 Mar; 104(908):115-7. PubMed ID: 2011292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
    Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
    Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 2020 American College of Rheumatology Guideline for the Management of Gout.
    FitzGerald JD; Dalbeth N; Mikuls T; Brignardello-Petersen R; Guyatt G; Abeles AM; Gelber AC; Harrold LR; Khanna D; King C; Levy G; Libbey C; Mount D; Pillinger MH; Rosenthal A; Singh JA; Sims JE; Smith BJ; Wenger NS; Bae SS; Danve A; Khanna PP; Kim SC; Lenert A; Poon S; Qasim A; Sehra ST; Sharma TSK; Toprover M; Turgunbaev M; Zeng L; Zhang MA; Turner AS; Neogi T
    Arthritis Rheumatol; 2020 Jun; 72(6):879-895. PubMed ID: 32390306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
    Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
    Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
    Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
    Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
    Latourte A; Bardin T; Richette P
    Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality of care in people requiring hospital admission for gout in Aotearoa New Zealand: a nationwide analysis.
    Murdoch R; Jones P; Greenwell J; Dalbeth N
    Intern Med J; 2022 Dec; 52(12):2136-2142. PubMed ID: 34339089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gout.
    Dalbeth N; Choi HK; Joosten LAB; Khanna PP; Matsuo H; Perez-Ruiz F; Stamp LK
    Nat Rev Dis Primers; 2019 Sep; 5(1):69. PubMed ID: 31558729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a prediction model for inpatient gout flares in people with comorbid gout.
    Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
    Ann Rheum Dis; 2020 Mar; 79(3):418-423. PubMed ID: 31811060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.